Current Active Clinical Trials:

Trial 1: A Randomized, Masked, Controlled Study of Intravitreal Iluvien Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Objective: To assess the efficacy of ILUVIEN® as baseline therapy in patients with early Diabetic Macular Edema (DME). To assess the effects of ILUVIEN® on Patient Reported Outcomes (PRO) of visual functioning and quality of life. To assess the safety and tolerability of ILUVIEN® and aflibercept combination in DME patients.

Trial 2: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

Objective: To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 0.5 mg ranibizumab, in participants with neovascular AMD.

Trial 3: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Objective: To evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

Trial 4: Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM (Protocol AM)

Objective: Compare visual acuity outcomes at 36 months between eyesrandomized to immediate versus deferred surgery.

If you have any questions or want to learn more about the current ongoing trials, please fill out the form below or call our office at 818-552-5040/310-659-2200 and speak with our Clinical Research Coordinator, Fadi Shaya.